Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Pulse DN-101 (Asentar) in Myelodysplastic Syndrome
NCT00057031Phase 2Unknown
- Sponsor
- Novacea
- Start
- Nov 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Asentar in myelodysplastic syndrome (MDS), sponsored by Novacea. Status: unknown.
02
Drugs
Asentar
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00057031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00057031.